Drug intelligence / Profile preview

Teyiquan

Development stage: Unknown
Lead developer: Chongqing Pharscin Pharmaceutical

Overview

Teyiquan is a total nutritional formula for Special Medical purposes, developed by Chongqing Pharscin Pharmaceutical Co., Ltd. It is designed to provide comprehensive nutritional support and adequacy for cancer patients, particularly those undergoing treatment for conditions such as esophageal and esophagogastric junction cancer and head and neck cancer. The formula aims to improve the nutritional status of patients, support recovery, and potentially enhance the efficacy of concurrent cancer therapies, while also addressing issues like cancer-related sarcopenia.

Brand names: Teyiquan

Beyond the preview

Go deeper on Teyiquan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Teyiquan.

Explore the full profile